

Attorney Docket No.: 3745.234-US
Serial No.: 09/754,723
Filed: January 4, 2001
Inventor: Ole Kirk
Title: Use of A Peptide
Via Facsimile No.: 571-273-8300

AMENDMENTS TO THE CLAIMS

The following listing of the claims replaces all prior claims presented in the application.

1-14. (Canceled)

15. (Currently amended) A method for treating type 2 diabetes, said method comprising administering to a patient in need of said treatment i) an effective amount of metformin via oral administration and ii) an effective amount of an insulinotropic GLP-1 related peptide via injection or infusion, where said insulinotropic GLP-1 related peptide is selected from the group consisting of GLP-I (7-37), GLP-1 (7-36)-amide, [[or]] an analogue of GLP-1 (7-37) [[or]] and an analogue of GLP-1 (7-36)-amide.

16. (Previously presented) The method of claim 15, wherein said insulinotropic GLP-1 related peptide is GLP-1 (7-36) amide.

17. (Previously presented) The method of claim 15, wherein said insulinotropic GLP-1 related peptide is an analogue of GLP-1 (7-37).

18. (Previously presented) The method of claim 17, wherein said analogue of GLP-1 {7-37} has one amino acid of GLP-I (7-37) exchanged by another amino acid.

19. (Previously presented) The method of claim 21, wherein said insulinotropic GLP-1 related peptide is a functional derivative of an analogue of GLP-1 (7-37).

20. (Previously presented) The method of claim 19, wherein said analogue of GLP-1 (7-37) has one amino acid of GLP-1(7-37) exchanged by another amino acid.

21. (Currently amended) A method for treating type 2 diabetes, said method comprising administering to a patient in need of said treatment i) an effective amount of metformin via oral administration and ii) an effective amount of an insulinotropic GLP-1 related peptide via injection or infusion, where said insulinotropic GLP-1 related peptide is selected

Attorney Docket No.: 3745.234-US
Serial No.: 09/754,723
Filed: January 4, 2001
Inventor: Ole Kirk
Title: Use of A Peptide
Via Facsimile No.: 571-273-8300

from the group consisting of a functional derivative of GLP-1 (7-37), a functional derivative of GLP-1 (7-36) amide, [[or]] a functional derivative of an analogue of GLP-1(7-37) [[or]] and a functional derivative of an analogue of GLP-1 (7-36) amide.

22. (Currently amended) A method for treating type 2 diabetes, said method comprising administering to a patient in need of said treatment an amount of metformin and an amount of an insulintropic peptide effective to treat said type 2 diabetes wherein the insulintropic peptide is an insulintropic GLP-1 related peptide selected from the group consisting of GLP-1 (7-37), GLP-1 (7-36) amide, an analogue of GLP-1 (7-37), an analogue of GLP-1 (7-36) amide, a functional derivative of GLP-1 (7-37), a functional derivative of GLP-1 (7-36) amide, a functional derivative of an analogue of GLP-1 (7-37) and a functional derivative of an analogue of GLP-1 (7-36) amide.

23. (Currently amended) The method of claim 22, wherein the insulintropic peptide is an insulintropic GLP-1 related peptide selected from the group consisting of GLP-1 (7-37), GLP-1 (7-36) amide, [[or]] an analogue of GLP-1 (7-37) [[or]] and an analogue of GLP-1 (7-36) amide.

24. (Currently amended) The method of claim 22, wherein the insulintropic peptide is an insulintropic GLP-1 related peptide selected from the group consisting of a functional derivative of GLP-1 (7-37), GLP-1 (7-36) amide, [[or]] a functional derivative of an analogue of GLP-1 (7-37) [[or]] and a functional derivative of an analogue of GLP-1 (7-36) amide.

25. (Previously presented) The method of claim 23, wherein said insulintropic GLP-1 related peptide is GLP-1 (7-36) amide.

26. (Previously presented) The method of claim 23, wherein said insulintropic GLP-1 related peptide is an analogue of GLP-1 (7-37).

27. (Previously presented) The method of claim 26, wherein said analogue of

Attorney Docket No.: 3745.234-US
Serial No.: 09/754,723
Filed: January 4, 2001
Inventor: Ole Kirk
Title: Use of A Peptide
Via Facsimile No.: 571-273-8300

GLP-I (7-37) has one amino acid of GLP-1 (7-37) exchanged by another amino acid.

28. (Previously presented) The method of claim 24, wherein said insulintropic GLP-1 related peptide is a functional derivative of an analogue of GLP-1 (7-37).

29. (Previously presented) The method of claim 28, wherein said analogue of GLP-1 (7-37) has one amino acid of GLP-1(7-37) exchanged by another amino acid.

30. (Previously presented) The method of claim 22, wherein the insulintropic peptide is administered to the subject via injection or infusion.

31. (Previously presented) The method of claim 22, wherein the metformin is administered to the subject orally.

32. (Previously presented) The method of claim 22, wherein said metformin is administered to the subject orally and said insulintropic peptide is administered to the subject via injection or infusion.